SG&A Efficiency Analysis: Comparing United Therapeutics Corporation and Walgreens Boots Alliance, Inc.

SG&A Trends: United Therapeutics vs. Walgreens Boots

__timestampUnited Therapeutics CorporationWalgreens Boots Alliance, Inc.
Wednesday, January 1, 201438128700017992000000
Thursday, January 1, 201545261200022400000000
Friday, January 1, 201631680000023910000000
Sunday, January 1, 201733010000023813000000
Monday, January 1, 201826580000024694000000
Tuesday, January 1, 201933620000023557000000
Wednesday, January 1, 202042390000025436000000
Friday, January 1, 202146700000024586000000
Saturday, January 1, 202248700000027295000000
Sunday, January 1, 202347710000034205000000
Monday, January 1, 202428113000000
Loading chart...

Unlocking the unknown

SG&A Efficiency: A Tale of Two Giants

In the world of corporate finance, Selling, General, and Administrative (SG&A) expenses are a critical measure of operational efficiency. This analysis compares United Therapeutics Corporation and Walgreens Boots Alliance, Inc. over a decade, from 2014 to 2023.

United Therapeutics Corporation

United Therapeutics has shown a steady increase in SG&A expenses, peaking in 2022 with a 30% rise from 2014. This growth reflects strategic investments in research and development, crucial for a biotech firm.

Walgreens Boots Alliance, Inc.

Walgreens, a retail giant, has consistently maintained higher SG&A expenses, with a notable 44% increase from 2014 to 2023. This trend underscores its expansive retail operations and global reach.

Conclusion

While both companies have distinct operational models, their SG&A trends highlight strategic priorities. Missing data for United Therapeutics in 2024 suggests a need for updated insights.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025